HCA Healthcare (HCA) Q4 2025 earnings review
Solid Beat, but 2026 Guidance Signals a Sharp Braking
HCA closed 2025 with strong headline numbers, beating on both Revenue (+6.7%) and Net Income (+31%). However, the quality of the beat is colored by favorable comparisons to a hurricane-impacted 2024. While financials improved, operational volume metrics stalled—ER visits were barely up (+0.5%) and surgeries flatlined. The real story lies in the 2026 guidance: management forecasts a significant deceleration, with implied EBITDA growth slowing to ~3% (down from ~12% in FY25), citing policy headwinds including the potential expiration of enhanced premium tax credits.
🐂 Bull Case
Despite volume softness, HCA expanded Adjusted EBITDA margins to 21.1% (up 80bps YoY). Salaries and benefits as a % of revenue dropped to 42.8%, proving the efficacy of their 'resiliency' cost-cutting programs.
The company repurchased $2.6 billion in stock in Q4 alone and authorized a new $10 billion program. This aggressive buyback pace provides a high floor for EPS even if operational growth slows.
🐻 Bear Case
Core operational metrics are flashing yellow. Same-facility inpatient surgeries were flat (0.0%) and outpatient surgeries declined (-0.5%). ER visit growth decelerated to 0.5% from 4.0% in Q1. Pricing, not volume, is carrying the P&L.
2026 guidance explicitly flags the expiration of enhanced premium tax credits and 'One Big Beautiful Bill Act' implementation. The forecasted ~3% EBITDA growth for 2026 is a fraction of the double-digit growth investors enjoyed in 2025.
⚖️ Verdict: ⚪
Neutral. Current financial execution is excellent, particularly on margins, but the underlying volume trends are deteriorating. The 2026 guidance suggests the 'easy money' phase of recovery is over, replaced by policy headwinds and slower growth.
Key Themes
Volume Momentum is Fading
After a strong start to 2025, core volume metrics have decelerated significantly. Emergency Room visits, often a leading indicator for admissions, slowed to +0.5% YoY in Q4 compared to +4.0% in Q1. More concerningly, high-margin surgery volumes turned negative or flat. If this trend persists, HCA loses a key lever for covering fixed costs.
Cost Efficiency Driving Margins
HCA continues to squeeze efficiencies out of its operations. Salaries and benefits dropped to 42.8% of revenue (vs 43.3% prior year). Adjusted EBITDA grew 10.8%, outpacing revenue growth of 6.7%. This positive operating leverage is critical as top-line growth is guided to slow in 2026.
Pricing Power Holds Up
With volumes flat, growth was driven by yield. Same facility revenue per equivalent admission increased 2.9% YoY. This indicates HCA is successfully navigating payer mix shifts and reimbursement rates, though relying solely on price is riskier than balanced volume/price growth.
Cash Flow Divergence
While Net Income soared 30%, Cash Flow from Operations actually *declined* YoY ($2.36B vs $2.56B). Management cites $1.3 billion in deferred tax payments made in Q4. While a timing issue, this cash drain reduced the immediate liquidity buffer compared to the earnings headline.
Policy Headwinds (EPTC & Tariffs)
The guidance text for 2026 is littered with caveats: 'impact of trade policies, including tariffs' and 'expiration of the enhanced premium tax credits.' The company is clearly baking in a conservative scenario regarding the healthcare exchanges, which have been a major tailwind for payer mix in recent years.
Other KPIs
Accelerating. Up 10.8% YoY. This result benefited from a clean comparison against 24Q4, which suffered ~$200M in hurricane damages. Even adjusting for that, underlying performance was solid.
Aggressive. HCA bought back 5.4 million shares in the quarter. With a new $10 billion authorization (approx 16% of market cap), management is signaling the stock is undervalued, or they lack better M&A targets.
Negative impact on Q4 Operating Cash Flow. Tax payments deferred from April 2025 (due to Tennessee weather relief) were paid in Q4, causing a temporary divergence between Net Income and OCF.
Guidance
Decelerating. The midpoint ($78.25B) implies ~3.5% YoY growth, down significantly from the 7.1% growth achieved in FY25. This suggests management expects volume headwinds or pricing pressure to persist.
Decelerating. The midpoint ($16.0B) implies just 2.8% growth vs FY25. This is a major slowdown from the 12% growth seen this year and implies margin expansion may have peaked.
Decelerating. Midpoint growth of ~7% is healthy but pales in comparison to the ~29% EPS growth delivered in FY25. Buybacks will likely drive most of this growth given the flat EBITDA outlook.
Stable. Consistent with FY25 levels, indicating continued investment in facility upgrades and capacity despite the slower growth outlook.
Key Questions
Surgery Volume Weakness
Inpatient surgeries were flat and outpatient surgeries declined in Q4. Is this a result of market share loss, or a broader industry slowdown? What gives you confidence these will return to growth in 2026?
2026 EBITDA Deceleration
The midpoint of 2026 guidance implies less than 3% EBITDA growth. How much of this compression is specific to the expiration of Enhanced Premium Tax Credits, and do you have mitigation plans if policy changes are worse than expected?
Tariff Exposure
Your guidance mentions 'impact of trade policies, including tariffs.' Can you quantify your supply chain exposure to potential new tariffs, specifically regarding medical supplies and equipment sourcing?
Capacity vs Demand
With occupancy relatively high at 72-73%, but ER and surgery growth stalling, are you facing capacity constraints in high-demand markets, or is the demand softening?